Trial Profile

A clinical trial of AR-712 (cocktail of fully human mAbs AR-711 and AR-713) for COVID-19

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 26 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AR-712 (Primary)
Indications COVID 2019 infections; Respiratory tract disorders
Focus Adverse reactions

Most Recent Events

10 Nov 2021 According to an Aridis Pharmaceutical media release, clinical trials for AR-712 are expected to commence in 1H2022.
12 Aug 2021 According to an Aridis Pharmaceutical media release, clinical trials for AR-712 are expected to commence towards the end of 2021.
11 May 2021 According to an Aridis Pharmaceutical media release, a clinical Phase 1/2 study is expected to be launched in 2H 2021.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com